English to Russian Medical Medical: Pharmaceuticals

ХХХХ key criteria for patients:
≥18 years of age
Histologic demonstration of transitional cell carcinoma of the urothelium
Stage IV disease
Documented progression of disease prior to randomization
Only one line of prior systemic treatment for metastatic urothelial cancer
Subjects must meet appropriate molecular eligibility criteria (as determined by central laboratory screening): tumours must have at least 1 of the following translocations:
FGFR2-BICC1, FGFR2-CASP7, FGFR3-TACC3, FGFR3-BAIAP2L1; or 1 of the following FGFR3 gene mutations:
R248C, S249C, G370C, Y373C
Additional criteria must be met to join the study.